Retrospective US database analysis of drug utilization patterns, health care resource use, and costs associated with adjuvant interferon alfa-2b therapy for treatment of malignant melanoma following surgery
Michelle D Hackshaw,1 Arun Krishna,2 David J Mauro31,2Global Health Outcomes, Merck, Sharpe and Dohme Corporation, Whitehouse Station, NJ, USA; 3Clinical Research, Merck Research Laboratories, Upper Gwynedd, PA, USABackground: The purpose of this study was to identify a real-world US population havi...
Saved in:
Main Authors: | Krishna A (Author), Hackshaw MD (Author), Mauro DJ (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2012-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Retrospective analysis of drug utilization, health care resource use, and costs associated with IFN therapy for adjuvant treatment of malignant melanoma
by: Zhang Y, et al.
Published: (2015) -
Cost-Utility Analysis of Nivolumab in Adjuvant Treatment of Melanoma in France
by: Bruno Bregman, et al.
Published: (2020) -
Comparison of peginterferon alfa-2a and alfa-2b for treatment of patients with chronic hepatitis C:a retrospective study using the Japanese Interferon Database
by: Sato I, et al.
Published: (2014) -
A Case of Malignant Melanoma with In-Transit Metastasis That Responded to Intravenous Infusion of Interferon-β
by: Masaru Arima, et al.
Published: (2014) -
Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers
by: Marisa Boff Costa, et al.
Published: (2018)